There is no FDA-approved medicine in the United States that contains ipamorelin, and FDA’s own advisers have voted unanimously against letting pharmacies compound it. The only trial that gave ipamorelin to patients as a treatment missed its main endpoint, and two people in the ipamorelin group died, deaths the investigators judged possibly related to the drug. In healthy volunteers, the entire human record is one dose-escalation study in which each intravenous infusion produced a single pulse of growth hormone. That is the whole clinical file, and it is a great deal thinner than most pages selling ipamorelin will tell you.<\/p>\n
That is the direct answer to what ipamorelin does: it makes the pituitary release growth hormone in a short burst. It has never been shown to do the things it is sold for. The same answer follows, with the paperwork attached.<\/p>\n
Ipamorelin is a five-amino-acid peptide. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and it was described by Raun and colleagues in 1998 as “the first selective growth hormone secretagogue” (PubMed 9849822<\/a>). It works at the ghrelin receptor, the same receptor the body uses to trigger hunger and growth hormone release.<\/p>\n The selling point was selectivity, and it was real in animals. In conscious swine, older secretagogues such as GHRP-6 and GHRP-2 raised ACTH and cortisol alongside growth hormone. Ipamorelin did not, even at doses more than 200 times the dose needed for half its growth hormone effect. That finding came from pigs and rat pituitary cells, not from people.<\/p>\n The human pharmacokinetic study is where the record gets narrow. Gobburu and colleagues ran a dose-escalation study in healthy male volunteers, with eight healthy male volunteers at each of five intravenous infusion rates ranging from 4.21 to 140.45 nanomoles per kilogram over 15 minutes (PubMed 10496658<\/a>, Pharmaceutical Research, 1999). Growth hormone peaked about 40 minutes after each infusion, the peptide’s terminal half-life was roughly two hours, and the response was a single pulse that faded to negligible levels. Healthy volunteers only, no disease, no outcomes measured beyond hormone concentrations. That is the study that gets cited when a sales page says ipamorelin “raises growth hormone.”<\/p>\n Ipamorelin’s one shot at becoming a medicine was postoperative ileus, the paralysis of the bowel that follows abdominal surgery. Beck, Sweeney, McCarter and the Ipamorelin 201 Study Group ran a multicenter, double-blind, placebo-controlled phase 2 trial published in the International Journal of Colorectal Disease in December 2014 (PubMed 25331030<\/a>, registered as NCT00672074<\/a>).<\/p>\n The design: 117 patients enrolled, 114 in the safety population, adults after small or large bowel resection. They received 0.03 milligrams per kilogram of ipamorelin by intravenous infusion twice daily, or placebo, from postoperative day 1 through day 7 or discharge. This is a hospital infusion protocol in surgical patients. It is not a subcutaneous injection and it is not a wellness protocol, which matters for reasons that come up below.<\/p>\n The primary endpoint, time from first dose to tolerating a standardized solid meal, came in at 25.3 hours on ipamorelin and 32.6 hours on placebo. The difference did not reach significance; the reported p value was 0.15. Treatment-emergent adverse events were reported by 87.5% of ipamorelin patients and 94.8% of placebo patients, and the most common were nausea, vomiting and abdominal distension.<\/p>\n Then the part that does not appear on the sales pages. Two patients in the ipamorelin group died from fatal serious adverse events. Both had undergone bowel resection for colon cancer and both developed anastomotic leak. The investigators recorded the primary causes as hyperkalemia in a patient with aortic clots, sepsis with perforated ulcer and renal failure, and sepsis with pneumonia, and they judged both deaths possibly related to the study drug.<\/p>\n The paper’s own conclusion reads that ipamorelin 0.03 milligrams per kilogram twice daily for up to seven days “was well tolerated.” Two deaths judged possibly related to the drug, in a trial of 114 patients, inside a conclusion that says well tolerated. Both statements are in the published record, and a reader deciding what to inject deserves to see both.<\/p>\n FDA reviewed ipamorelin for the October 29, 2024 compounding advisory meeting and evaluated two uses: growth hormone deficiency and postoperative ileus. Its conclusion on effectiveness, in the agency’s briefing document dated August 19, 2024, was blunt: “We conclude based on available clinical information that the evidence of effectiveness for GHD or POI is limited for any ROA, and there are no data to support the effectiveness of ipamorelin (free base) or ipamorelin acetate for the proposed SC route of administration for these medical conditions” (FDA briefing document<\/a>).<\/p>\n SC means subcutaneous, the route a telehealth patient would use at home. The agency is saying the evidence does not exist for it. The one patient trial delivered the drug by intravenous infusion in a hospital.<\/p>\n FDA’s separate safety page lists ipamorelin acetate in category 2 under the 503B interim policy, dated September 29, 2023 (FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks<\/a>). The stated concerns are immunogenicity from aggregation, peptide-related impurities, and the difficulty of characterizing a peptide that contains unnatural amino acids. The same page notes that a published study identified serious adverse events including death when ipamorelin was given intravenously to improve gastric motility, while adding that FDA lacks safety information for certain other injectable routes.<\/p>\n Compounding law matters here. A state-licensed pharmacy working under section 503A can only use a bulk substance that has a USP monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list. Ipamorelin has none of those three. That is why the nomination existed in the first place.<\/p>\n On October 29, 2024, FDA’s Pharmacy Compounding Advisory Committee took up ipamorelin free base and ipamorelin acetate. For the free base the vote was 0 yes, 12 no, 1 abstention. For the acetate it was 0 yes, 12 no, 1 abstention (final summary minutes, approved January 15, 2025<\/a>).<\/p>\n The minutes record why. Members who voted no “agreed that there was a lack of information supporting safety and efficacy shown in the available data for the use of Ipamorelin (free base) for GHD and postoperative ileus.” One member added that the high frequency of a drug being prescribed does not necessarily mean the drug is safe and effective. That sentence is the entire argument against buying a peptide because a lot of people seem to be taking it.<\/p>\n An advisory vote is not a final rule, and FDA has not issued one for ipamorelin. The vote does establish one thing: the people FDA asks to weigh safety evidence looked at the file and found it empty in both directions.<\/p>\n No trial has measured ipamorelin against muscle mass, fat mass, sleep quality, skin, tendon healing, recovery time, or libido in humans. Not one published study has compared it to placebo on any of those outcomes. The single patient trial measured how fast bowel surgery patients tolerated a meal, and it failed to separate from placebo.<\/p>\n A growth hormone pulse is also not the same thing as a result. Growth hormone works largely by raising IGF-1, and adult growth hormone therapy is a monitored prescription for diagnosed deficiency, not a wellness optimization. The FDA briefing document points out that approved therapies already exist for adults with all forms of growth hormone deficiency, and that professional society guidelines do not discuss ipamorelin for any use at all.<\/p>\n The unknown part is larger than the known part. No published study covers long-term use of repeated subcutaneous ipamorelin in healthy adults, and no patient registry tracks the people who use it. The class has its own documented history of harm: CJC-1295, another growth hormone secretagogue sold through the same channels, drew FDA’s attention when a trial subject’s racing heart was recorded in the FDA file<\/a>. Ipamorelin has not earned an exemption from that safety list FDA keeps on peptides<\/a>, and the pattern is familiar: MOTS-c had papers cited for it and no human data behind them<\/a> when FDA read the same file.<\/p>\n If a clinic, medspa or website offers ipamorelin, the questions are short and the answers are checkable.<\/p>\n A clinic that cannot answer the first question is not selling a treatment with a file behind it. Our clinic directory<\/a> lists clinics by city, and we tell readers to check each clinic’s license and prescribing record themselves before paying anything. The compounds index<\/a> shows which peptides have a reviewed page here and which do not.<\/p>\n No. No FDA-approved drug product contains ipamorelin. FDA reviewed ipamorelin only as a bulk drug substance proposed for compounding, and its Pharmacy Compounding Advisory Committee voted 12 to 0 against adding it to the 503A bulks list in October 2024.<\/p>\n It is not available as an approved prescription medicine. Compounding it is restricted: under section 503A a pharmacy needs a USP monograph, an approved drug component, or a place on FDA’s bulks list, and ipamorelin has none of the three. FDA also lists ipamorelin acetate in category 2 under the 503B interim policy because of safety concerns.<\/p>\n In a dose-escalation study in healthy male volunteers, each intravenous infusion produced a single pulse of growth hormone that peaked about 40 minutes after dosing, with a peptide half-life near two hours. That study measured hormone concentrations only. It did not measure muscle, fat, sleep or recovery.<\/p>\n Once, as a treatment. A phase 2 trial in 117 bowel surgery patients compared intravenous ipamorelin with placebo for postoperative ileus, and the primary endpoint was not met: median time to tolerating a solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, with a reported p value of 0.15. Two patients in the ipamorelin group died, and investigators judged those deaths possibly related to the drug.<\/p>\n That cannot be answered from published human data. There is no long-term study of repeated subcutaneous use in healthy adults, and FDA’s stated concerns include immunogenicity, aggregation and peptide-related impurities. The only placebo-controlled patient trial reported serious adverse events in 10 of 56 ipamorelin patients and 9 of 58 placebo patients, including the two deaths judged possibly related.<\/p>\n No human trial has measured either. The one patient trial measured bowel recovery after surgery. Claims about body composition come from the mechanism, not from a study in people.<\/p>\n The ileus trial used 0.03 milligrams per kilogram by intravenous infusion twice daily in hospitalized surgical patients, and the volunteer study used single intravenous infusions from 4.21 to 140.45 nanomoles per kilogram over 15 minutes. Those are research protocols under supervision, not dosing advice. Anyone considering this peptide should take the question to a licensed prescriber who can review their history and monitor them.<\/p>\n This article is for information. It is not medical advice, and it is not a recommendation to use or avoid any product. Compounded peptides are not FDA-approved, doses vary by prescriber and pharmacy, and anyone considering treatment should consult a licensed clinician who can review their own history and monitor them.<\/p>\nThe Ileus Trial – 25.3 Hours Against 32.6, and Two Deaths<\/h2>\n
FDA – The Route Being Sold Was Not The Route Studied<\/h2>\n
The Vote – Twelve No, Zero Yes, One Abstention<\/h2>\n
What Ipamorelin Has Not Been Shown To Do<\/h2>\n
What To Ask Anyone Offering Ipamorelin<\/h2>\n
\n
Frequently Asked Questions<\/h2>\n
Is ipamorelin FDA approved?<\/h3>\n
Is ipamorelin legal to buy?<\/h3>\n
What does ipamorelin do to growth hormone in humans?<\/h3>\n
Has ipamorelin been tested in patients?<\/h3>\n
Is ipamorelin safe?<\/h3>\n
Does ipamorelin build muscle or burn fat?<\/h3>\n
What dose of ipamorelin did the trials use?<\/h3>\n
Sources<\/h2>\n
\n